UTHR Stock Summary and Trading Ideas (United Therapeutics | NASDAQ:UTHR)

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

United Therapeutics trades on the NASDAQ stock market under the symbol UTHR.

As of January 16, 2026, UTHR stock price declined to $464.93 with 368,343 million shares trading.

UTHR has a beta of 0.49, meaning it tends to be less sensitive to market movements. UTHR has a correlation of 0.05 to the broad based SPY ETF.

UTHR has a market cap of $20.02 billion. This is considered a Large Cap stock.

Last quarter United Therapeutics reported $800 million in Revenue and $7.16 earnings per share. This fell short of revenue expectation by $-15 million and exceeded earnings estimates by $.23.

In the last 3 years, UTHR traded as high as $519.99 and as low as $204.44.

The top ETF exchange traded funds that UTHR belongs to (by Net Assets): VTI, IJH, VB, VBR, VXF.

UTHR has outperformed the market in the last year with a return of +26.9%, while the SPY ETF gained +18.1%. In the last 3 month period, UTHR beat the market returning +7.5%, while SPY returned +5.0%. However, in the most recent 2 weeks UTHR has underperformed the stock market by returning -6.4%, while SPY returned +1.2%.

UTHR support price is $464.30 and resistance is $479.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that UTHR shares will trade within this expected range on the day.